-
3 Biologics Maker, Specialty Ingredient and Pharmacy Retail Stocks With a Strong Future Roadmap: Shilpa Medicare, Viyash Scientific and Medplus Health Services
- October 14, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
No Comments
Shilpa Medicare, Viyash Scientific and Medplus Health Services compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.
-
3 Branded Formulation, Biologics and Pharma Service Stocks With a Strong Future Roadmap: Mankind Pharma, Shilpa Medicare and Indegene
- October 14, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Mankind Pharma, Shilpa Medicare and Indegene compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.
-
3 Fermentation Ingredient, Biologics and Global Generic Stocks With a Strong Future Roadmap: Concord Biotech, Shilpa Medicare and Aurobindo Pharma
- October 14, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Concord Biotech, Shilpa Medicare and Aurobindo Pharma compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.
-
Shilpa Medicare’s 238% Rally Now Faces a Real Earnings Test
- September 25, 2026
- Posted by: Chaitanya Auti
- Category: News
Shilpa Medicare’s 238% 2026 rally faces an earnings test after Q1FY27 revenue rose 43% and profit jumped 115%, partly aided by a one-time tax reversal.